Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 27, 2014New England Journal of Medicine

Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

Alice T. ShawAlice T. ShawUniversité Paris-SudSOSai‐Hong Ignatius OuUniversity of California, IrvineYung‐Jue BangYung‐Jue BangRutgers, The State University of New Jersey

Discussion

Loading...

Member takes

Implication

Randomized trial demonstrates antitumor activity of crizotinib in advanced ROS1-rearranged NSCLC, highlighting treatment potential.

Key Points

  • This research aims to evaluate the effectiveness of crizotinib in patients with ROS1-rearranged non-small-cell lung cancer (NSCLC).
  • Single-arm treatment of patients with advanced ROS1-rearranged NSCLC
  • Antitumor activity assessed following administration of crizotinib
  • ClinicalTrials.gov number, NCT00585195
  • Crizotinib exhibited marked antitumor activity in patients diagnosed with advanced ROS1-rearranged NSCLC.

Cite This Study

Shaw et al. (2014) studied this question.

synapsesocial.com/papers/69d7dab7ec32c73b01ae30bfhttps://doi.org/10.1056/nejmoa1406766
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Fusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with an interstitial del(6)(q21q21)2003 · 217 citations
  2. 2Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer2012 · 475 citations
  3. 3Characterization of an Activated Human ros Gene1986 · 43 citations
  4. 4Toxicity and response criteria of the Eastern Cooperative Oncology Group1982 · 11,821 citations
  5. 5Characterization of an activated human ros gene.1986 · 117 citations